Answers are grounded in this paper and cite their sources.
Case reports highlight therapeutic approaches for hepatic relapses in systemic juvenile idiopathic arthritis with macrophage activation syndrome.
We read with interest the manuscript entitled "Hepatic Manifestations in Systemic Juvenile Idiopathic Arthritis and Macrophage Activation Syndrome" by Eloseily et al,¹ describing 4 patients with systemic juvenile idiopathic arthritis (sJIA) complicated by macrophage activation syndrome (MAS) and hepatic involvement and treated with emapalumab. We report our experience with this subgroup of patients, describing 2 cases treated at Meyer Children9s Hospital in which patients experienced multiple hepatic relapses requiring a combined treatment approach.
No takes yet. Share an insight, caveat, or question.
Romano et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: